Kyverna Research Development from 2010 to 2026
| KYTX Stock | 7.93 0.66 9.08% |
Research Development | First Reported 2010-12-31 | Previous Quarter 129.3 M | Current Value 135.8 M | Quarterly Volatility 39.2 M |
Check Kyverna Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Kyverna Therapeutics' main balance sheet or income statement drivers, such as Net Interest Income of 18.4 M, Interest Income of 18.5 M or Depreciation And Amortization of 1.5 M, as well as many indicators such as Price To Sales Ratio of 136, Dividend Yield of 0.0 or PTB Ratio of 0.46. Kyverna financial statements analysis is a perfect complement when working with Kyverna Therapeutics Valuation or Volatility modules.
Kyverna | Research Development | Build AI portfolio with Kyverna Stock |
The evolution of Research Development for Kyverna Therapeutics Common provides essential context for understanding the company's financial health trajectory. By analyzing this metric's behavior over time, investors can assess whether recent trends align with long-term patterns, and how Kyverna Therapeutics compares to historical norms and industry peers.
Latest Kyverna Therapeutics' Research Development Growth Pattern
Below is the plot of the Research Development of Kyverna Therapeutics Common over the last few years. It is Kyverna Therapeutics' Research Development historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Kyverna Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Research Development | 10 Years Trend |
|
Research Development |
| Timeline |
Kyverna Research Development Regression Statistics
| Arithmetic Mean | 44,968,829 | |
| Geometric Mean | 35,636,423 | |
| Coefficient Of Variation | 87.19 | |
| Mean Deviation | 28,937,504 | |
| Median | 25,852,000 | |
| Standard Deviation | 39,209,966 | |
| Sample Variance | 1537.4T | |
| Range | 110M | |
| R-Value | 0.71 | |
| Mean Square Error | 815.7T | |
| R-Squared | 0.50 | |
| Significance | 0 | |
| Slope | 5,504,566 | |
| Total Sum of Squares | 24598.7T |
Kyverna Research Development History
About Kyverna Therapeutics Financial Statements
Kyverna Therapeutics investors use historical fundamental indicators, such as Kyverna Therapeutics' Research Development, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Kyverna Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Research Development | 129.3 M | 135.8 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Kyverna Stock Analysis
When running Kyverna Therapeutics' price analysis, check to measure Kyverna Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kyverna Therapeutics is operating at the current time. Most of Kyverna Therapeutics' value examination focuses on studying past and present price action to predict the probability of Kyverna Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kyverna Therapeutics' price. Additionally, you may evaluate how the addition of Kyverna Therapeutics to your portfolios can decrease your overall portfolio volatility.